AstraZeneca's venture investing has evolved from the traditional MedImmune Ventures model ($400M, 2002-2013+) to a current structure centered on the BioVentureHub (an innovation campus) and strategic partnerships.
In 2024, AstraZeneca acquired Fusion Pharmaceuticals for radiopharmaceuticals. The AZ-CICC Healthcare Investment Fund targets China medical and biotech investments. Partners include Dai...
New York, United States
France
New York, United States
London, United Kingdom
Menlo Park, California, United States
Basel, Switzerland